|
1
|
Sodano F, Cristiano C, Rolando B, Marini E, Lazzarato L, Cuozzo M, Albrizio S, Russo R, Rimoli MG. Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs. Pharmaceuticals (Basel) 2022; 15:ph15050552. [PMID: 35631377 PMCID: PMC9142922 DOI: 10.3390/ph15050552] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 04/25/2022] [Accepted: 04/27/2022] [Indexed: 02/04/2023] Open
Abstract
Carbohydrates are one of the most abundant and important classes of biomolecules. The variety in their structures makes them valuable carriers that can improve the pharmaceutical phase, pharmacokinetics and pharmacodynamics of well-known drugs. D-galactose is a simple, naturally occurring monosaccharide sugar that has been extensively studied for use as a carrier and has proven to be valuable in this role. With the aim of validating the galactose-prodrug approach, we have investigated the galactosylated prodrugs ibuprofen, ketoprofen, flurbiprofen and indomethacin, which we have named IbuGAL, OkyGAL, FluGAL and IndoGAL, respectively. Their physicochemical profiles in terms of lipophilicity, solubility and chemical stability have been evaluated at different physiological pH values, as have human serum stability and serum protein binding. Ex vivo intestinal permeation experiments were performed to provide preliminary insights into the oral bioavailability of the galactosylated prodrugs. Finally, their anti-inflammatory, analgesic and ulcerogenic activities were investigated in vivo in mice after oral treatment. The present results, taken together with those of previous studies, undoubtedly validate the galactosylated prodrug strategy as a problem-solving technique that can overcome the disadvantages of NSAIDs.
Collapse
Affiliation(s)
- Federica Sodano
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy; (B.R.); (E.M.); (L.L.)
- Correspondence: ; Tel.: +39-081-678-604
| | - Claudia Cristiano
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
| | - Barbara Rolando
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy; (B.R.); (E.M.); (L.L.)
| | - Elisabetta Marini
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy; (B.R.); (E.M.); (L.L.)
| | - Loretta Lazzarato
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy; (B.R.); (E.M.); (L.L.)
| | - Mariarosaria Cuozzo
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
| | - Stefania Albrizio
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
| | - Roberto Russo
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
| | - Maria Grazia Rimoli
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy; (C.C.); (M.C.); (S.A.); (R.R.); (M.G.R.)
| |
Collapse
|